Brief: Appili Therapeutics Ati-1701 Biodefense Vaccine Secures ~$14 Million Of Funding From U.S. Department Of Defense In Partnership With U.S. Air Force Academy

Appili Therapeutics

14/11/2022 12:50

Nov 14 (Reuters) - Appili Therapeutics Inc  APLI.TO :
    * APPILI THERAPEUTICS ATI-1701 BIODEFENSE VACCINE SECURES
~US$14
MILLION OF FUNDING FROM THE U.S. DEPARTMENT OF DEFENSE IN
PARTNERSHIP WITH THE U.S. AIR FORCE ACADEMY
    * APPILI THERAPEUTICS INC - ARMAND BALBONI HAS BEEN
APPOINTED AS
CHAIR OF BOARD OF DIRECTORS OF APPILI
    * APPILI THERAPEUTICS INC - DON CILLA, HAS BEEN PROMOTED TO
POSITION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER OF APPILI
    * APPILI THERAPEUTICS INC - ADDITIONAL BOARD CHANGES INCLUDE
IAN
MORTIMER STEPPING DOWN AS CHAIR OF BOARD AND DIRECTOR

Source text for Eikon:  ID:nBw7jjC3za 
Further company coverage:  APLI.TO